The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Fresenius Kabi LLC, Red Blood Cell (RBC) Exchange Sets used on AS104 Blood Cell Separation Devices: Class I Recall

December 21, 2010 9:30 am | by U.S. Food & Drug Administration | News | Comments

Use of the recalled product has led to removal of greater amounts of red blood cells than intended, resulting in hemodilution.


Analyst: Nursing home owners to get Medicare boost

December 21, 2010 8:45 am | by The Associated Press | News | Comments

Nursing home owners and operators likely will get a boost from changes in Medicare's payment system next year, an analyst said Tuesday.Despite the run-up in shares of real estate investment trusts that focus on senior care, Morgan Keegan analyst Robert Mains said the sector still will post...

Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences

December 21, 2010 7:35 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Dec. 21, 2010 /- Based on its recent analysis of the surface functionalization technologies market, Frost & Sullivan recognizes Cambridge, Mass.-based Semprus BioSciences with the 2010 Enabling Technology of the Year Award for Surface Functionalization...


On Average, 55 Percent of Surveyed U.S. Asthma Patients Say They Are Likely to Request a Switch to a Drug With Efficacy Comparable to Their Current Medication but Which is Dos...

December 21, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., Dec. 21, 2010 /- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an average of 55 percent of surveyed asthma patients in the U.S. report that they are likely or very likely to request a...


Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis

December 21, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

DURHAM, N.C., Dec. 21, 2010 /- bioMerieux, a world leader in the field of in vitro diagnostics, announced the results of a survey demonstrating that most critical care nurses are unaware of a simple diagnostic test that may dramatically improve outcomes for sepsis patients. The survey,...


Generational Equity Announces Sale of B-Pharm, Inc. dba Remedies Pharmacy to a Private Investment Group

December 21, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

DALLAS, Dec. 21, 2010 /- Generational Equity, a leading advisor to privately held and family-owned businesses for mergers, acquisitions, strategic growth initiatives, business valuation and exit planning announced the acquisition of its client, B-Pharm, Inc. dba Remedies Pharmacy,...


Cambridge Heart takes in $2.9M

December 21, 2010 6:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Cambridge Heart Inc., the Tewksbury-based developer of diagnostic heart tests for cardiac disease, has raised $2.9 million in a private placement, the company reported today.

PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis

December 21, 2010 5:30 am | by Bio-Medicine.Org | News | Comments

SOUTH PLAINFIELD, N.J., Dec. 21, 2010 /- PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). (Logo:...


Federal Register: Meetings: Advisory Committees; Tentative Schedule for 2011

December 21, 2010 4:34 am | by U.S. Food & Drug Administration | News | Comments

The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2011.

Biogen buys Neurimmune unit for up to $427M

December 21, 2010 4:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Biogen Idec Inc. has bought a subsidiary of Swiss firm Neurimmune Holding AG in a move that will give Biogen potential treatments for neurodegenerative disease like Parkinson's disease, at a total potential cost of $427 million.

Genzyme touts market potential for MS drug

December 21, 2010 4:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Genzyme Corp. appeared to go on the offensive Monday in making its point that the Cambridge biotech is worth more than the $69 per share price offered by Sanofi-aventis in its takeover bid.

Zimmer Finalizes Acquisition of Chinese Orthopaedic Implant Leader Beijing Montagne Medical Device Co., Ltd.

December 21, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

BEIJING, Dec. 21, 2010 /- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal care, today announced that it has completed the acquisition of Beijing Montagne Medical Device Co., Ltd.  The acquisition further enhances Zimmer's presence in the emerging Chinese...


INVO Bioscience Announces First Shipments of INVOcell Into Bolivia

December 21, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

BEVERLY, Mass., Dec. 21, 2010 /- INVO Bioscience, Inc. (OTC Bulletin Board: IVOB ), a medical device company focused on treatment options for patients diagnosed with infertility, today announced the initial shipments of the INVOcell device into Bolivia.  The initial order of INVOcell...


Microscopes fit within a miniaturized chip

December 21, 2010 3:37 am | by I-Micronews | News | Comments

Using a plate of silicon containing dozens of miniature lenses, scientists at Harvard University, United States, say they are very close to putting large capacity of microscopes used in their laboratories inside a device no bigger than a chip computer.

ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO

December 21, 2010 3:33 am | by RealWire | News | Comments

PHILADELPHIA, PA, 21 December 2010 - ERT, a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, today confirmed that the effective date of the previously announced retirement of Dr. Michael J. McKelvey, its President and CEO, is...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.